Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Heartseed, Inc. ( (JP:219A) ) is now available.
Heartseed Inc. announced the termination of its partnership with Novo Nordisk A/S, which was initially a significant collaboration in the cell therapy field. The company is addressing investor concerns about the impact on its stock price and future partnerships, emphasizing its recognition in the international market and the need for careful consideration in forming new alliances to enhance corporate value.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
More about Heartseed, Inc.
Heartseed Inc. operates in the biotechnology industry, focusing on cell therapy and regenerative medicine for heart failure. The company is known for its therapeutic program using allogeneic iPS cell-derived cardiomyocytes spheroids, targeting ischemic heart disease.
Average Trading Volume: 833,072
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen74.11B
For a thorough assessment of 219A stock, go to TipRanks’ Stock Analysis page.